FIELD: pharmaceuticals.
SUBSTANCE: invention refers to liquid compositions based on VEGF antagonists contained in pre-filled pharmaceutical syringes for intravitreal injection. Disclosed is a pre-filled pharmaceutical syringe having finished liquid sterilization, containing a liquid formulation based on VEGF antagonist, for example ranibizumab, in a pre-filled pharmaceutical syringe made of polyolefin, coated from the inside with a binder coating or a layer, a barrier coating or a layer and a coating or a layer which protects from the effect of pH. What is also presented is a kit consisting of several said syringes.
EFFECT: technical result—for VEGF antagonist, which is in finished sterilization of pre-filled pharmaceutical syringe, stability characteristics are achieved, comparable to those in glass container or exceeding them.
15 cl, 18 tbl, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL PACKAGING FOR OPHTHALMIC FORMULATIONS | 2016 |
|
RU2751510C2 |
| PRE-FILLED PLASTIC SYRINGE CONTAINING VEGF ANTAGONIST | 2015 |
|
RU2702748C2 |
| USE OF VEGF ANTAGONIST FOR TREATING RETINOPATHY OF PREMATURITY | 2014 |
|
RU2676303C2 |
| LIPOSOME FORMULATIONS | 2013 |
|
RU2680096C2 |
| LIPOSOMAL PREPARATIONS | 2013 |
|
RU2817350C2 |
| PECVD-COATING WITH APPLICATION OF ORGANOSILICON PRECURSOR | 2010 |
|
RU2550452C2 |
| GAS RELEASE PROCESS FOR INSPECTION OF COATED SURFACES | 2010 |
|
RU2523773C2 |
| APPLICATION OF ANTAGONIST VEGF IN TREATMENT OF CHORIORETINAL NEOVASCULAR DISTURBANCES AND DISORDERS OF PENETRATION IN PEDIATRIC PATIENTS | 2014 |
|
RU2676274C2 |
| USE OF SIROLIMUS FOR TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH PERSISTENT EDEMA | 2017 |
|
RU2765728C2 |
| METHODS OF INSPECTION OF GAS EMISSION VESSELS | 2011 |
|
RU2561759C2 |
